Key result
Emodin reduced pathological lung injury to 50% compared to 100% in untreated severe acute pancreatitis rats, and modulated different lncRNA-mRNA co-expression networks than dexamethasone.
Why the study?
Long non-coding RNA regulation networks related to severe acute pancreatitis-associated acute lung injury pathogenesis and drug treatment are unreported.
Does emodin alter lncRNA-mRNA networks in rats with severe acute pancreatitis-induced acute lung injury compared to dexamethasone or no treatment?
Does emodin alter lncRNA-mRNA networks in rats with severe acute pancreatitis-induced acute lung injury compared to dexamethasone or no treatment?
Absolute Event Rate: 50% vs 100%
p-value: p=<0.05
Emodin modulates different lncRNA-mRNA networks compared to dexamethasone in a rat model of severe acute pancreatitis-induced acute lung injury, suggesting it may be a suitable alternative or complementary therapy.
Emodin may attenuate experimental pancreatitis lung injury; leaves open its comparative efficacy and lncRNA mechanisms versus dexamethasone in clinical settings.
Long non-coding RNAs (lncRNAs) contribute to disease pathogenesis and drug treatment effects. Both emodin and dexamethasone (DEX) have been used for treating severe acute pancreatitis-associated acute lung injury (SAP-ALI). However, lncRNA regulation networks related to SAP-ALI pathogenesis and drug treatment are unreported. In this study, lncRNAs and mRNAs in the lung tissue of SAP-ALI and control rats, with or without drug treatment (emodin or DEX), were assessed by RNA sequencing. Results showed both emodin and DEX were therapeutic for SAP-ALI and that mRNA and lncRNA levels differed between untreated and treated SAP-ALI rats. Gene expression profile relationships for emodin-treated and control rats were higher than DEX-treated and -untreated animals. By comparison of control and SAP-ALI animals, more up-regulated than down-regulated mRNAs and lncRNAs were observed with emodin treatment. For DEX treatment, more down-regulated than up-regulated mRNAs and lncRNAs were observed. Functional analysis demonstrated both up-regulated mRNA and co-expressed genes with up-regulated lncRNAs were enriched in inflammatory and immune response pathways. Further, emodin-associated lncRNAs and mRNAs co-expressed modules were different from those associated with DEX. Quantitative polymerase chain reaction demonstrates selected lncRNA and mRNA co-expressed modules were different in the lung tissue of emodin- and DEX-treated rats. Also, emodin had different effects compared with DEX on co-expression network of lncRNAs Rn60_7_1164.1 and AABR07062477.2 for the blue lncRNA module and Nrp1 for the green mRNA module. In conclusion, this study provides evidence that emodin may be a suitable alternative or complementary medicine for treating SAP-ALI.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2021) studied Severe acute pancreatitis-induced acute lung injury (n=60). Emodin vs. Dexamethasone and Placebo (SAP model) was evaluated on Pathological lung injury (p=<0.05). Emodin reduced pathological lung injury to 50% compared to 100% in untreated severe acute pancreatitis rats, and modulated different lncRNA-mRNA co-expression networks than dexamethasone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: